BUZZ-Needham downgrades Hologic to 'hold' on 2025 growth hindrances

Reuters

Feb 04, 2025

BUZZ-Needham downgrades Hologic to 'hold' on 2025 growth hindrances

** Brokerage Needham downgrades medical device maker Hologic HOLX.O to "hold" from "buy", initiates coverage with a PT of $90

** Sees several headwinds that may lead to slower revenue and profit growth for the company in 2025

** Sees breast-health segment growth remaining weak ahead of the 2026 launch of Envision - the company's new 3D mammography platform, as consumers may defer purchasing from the company's existing platforms

** Says the U.S. Preventive Services Task Force's plans to add self-collected human papillomavirus (HPV) testing to its cervical cancer screening recommendations will hurt HOLX's cytology (pap test) business

** HOLX is expected to report Q1 results on Feb. 5, after reporting missed Q1 sales in its preliminary results on Jan. 12

** Eight of 22 brokerages rate the stock "buy" or higher, 13 "hold" and one "sell"; with a median PT of $85, according to data compiled by LSEG

** HOLX rose ~1% in 2024

(Reporting by Neil J Kanatt in Bengaluru)

((Neil.JKanatt@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2508121493"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2508121493\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2508121493?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-04 02:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2508121493","market":"us","top_or_hot":-1,"title":"BUZZ-Needham downgrades Hologic to 'hold' on 2025 growth hindrances","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Needham downgrades Hologic to 'hold' on 2025 growth hindrances </title></head><body><p>** Brokerage Needham downgrades medical device maker Hologic <span>HOLX.O</span> to \"hold\" from \"buy\", <span>initiates coverage with a PT of $90</span></p><p>** Sees several headwinds that may lead to slower revenue <span>and</span> profit growth for the company in 2025</p><p> <span>   ** Sees breast-health segment growth remaining weak ahead of the 2026 launch of Envision - the company's new 3D mammography platform, as consumers may defer purchasing from the company's existing platforms</span></p><p>** Says <span>the</span> U.S. Preventive Services Task Force's plans to add self-collected <span>human papillomavirus (HPV) </span>testing to its cervical cancer screening recommendations will hurt HOLX's cytology (pap test) business</p><p>** HOLX is expected to report Q1 results on Feb. 5, after reporting missed Q1 sales in its preliminary results on <span>Jan. 12</span></p><p>** Eight of 22 brokerages rate the stock \"buy\" or higher, 13 \"hold\" and one \"sell\"; with a median PT of $85, <span>according to data compiled by LSEG</span></p><p>** HOLX rose ~1% in 2024</p><p> (Reporting by Neil J Kanatt in Bengaluru)</p><p> ((Neil.JKanatt@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Needham downgrades Hologic to 'hold' on 2025 growth hindrances</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Needham downgrades Hologic to 'hold' on 2025 growth hindrances\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-04 02:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Needham downgrades Hologic to 'hold' on 2025 growth hindrances </title></head><body><p>** Brokerage Needham downgrades medical device maker Hologic <span>HOLX.O</span> to \"hold\" from \"buy\", <span>initiates coverage with a PT of $90</span></p><p>** Sees several headwinds that may lead to slower revenue <span>and</span> profit growth for the company in 2025</p><p> <span>   ** Sees breast-health segment growth remaining weak ahead of the 2026 launch of Envision - the company's new 3D mammography platform, as consumers may defer purchasing from the company's existing platforms</span></p><p>** Says <span>the</span> U.S. Preventive Services Task Force's plans to add self-collected <span>human papillomavirus (HPV) </span>testing to its cervical cancer screening recommendations will hurt HOLX's cytology (pap test) business</p><p>** HOLX is expected to report Q1 results on Feb. 5, after reporting missed Q1 sales in its preliminary results on <span>Jan. 12</span></p><p>** Eight of 22 brokerages rate the stock \"buy\" or higher, 13 \"hold\" and one \"sell\"; with a median PT of $85, <span>according to data compiled by LSEG</span></p><p>** HOLX rose ~1% in 2024</p><p> (Reporting by Neil J Kanatt in Bengaluru)</p><p> ((Neil.JKanatt@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HOLX","symbol_name":"豪洛捷","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nL4N3OU1GG:1","article_id":"2508121493","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2508121493","pubTimestamp":1738608574,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Needham downgrades Hologic to 'hold' on 2025 growth hindrances ** Brokerage Needham downgrades medical device maker Hologic HOLX.O to \"hold\" from \"buy\", initiates coverage with a PT of $90** Sees several headwinds that may lead to slower revenue and profit growth for the company in 2025    ** Sees breast-health segment growth remaining weak ahead of the 2026 launch of Envision - the company's new 3D mammography platform, as consumers may defer purchasing from the company's existing platforms** Says the U.S. Preventive Services Task Force's plans to add self-collected human papillomavirus  testing to its cervical cancer screening recommendations will hurt HOLX's cytology  business** HOLX is expected to report Q1 results on Feb. 5, after reporting missed Q1 sales in its preliminary results on Jan. 12** Eight of 22 brokerages rate the stock \"buy\" or higher, 13 \"hold\" and one \"sell\"; with a median PT of $85, according to data compiled by LSEG** HOLX rose ~1% in 2024  ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"HOLX":"豪洛捷"},"translate_title":"BUZZ-Needham将Hologic评级下调至“持有”以应对2025年增长障碍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOLX":0.9},"content_text":"BUZZ-Needham downgrades Hologic to 'hold' on 2025 growth hindrances ** Brokerage Needham downgrades medical device maker Hologic HOLX.O to \"hold\" from \"buy\", initiates coverage with a PT of $90** Sees several headwinds that may lead to slower revenue and profit growth for the company in 2025    ** Sees breast-health segment growth remaining weak ahead of the 2026 launch of Envision - the company's new 3D mammography platform, as consumers may defer purchasing from the company's existing platforms** Says the U.S. Preventive Services Task Force's plans to add self-collected human papillomavirus (HPV) testing to its cervical cancer screening recommendations will hurt HOLX's cytology (pap test) business** HOLX is expected to report Q1 results on Feb. 5, after reporting missed Q1 sales in its preliminary results on Jan. 12** Eight of 22 brokerages rate the stock \"buy\" or higher, 13 \"hold\" and one \"sell\"; with a median PT of $85, according to data compiled by LSEG** HOLX rose ~1% in 2024 (Reporting by Neil J Kanatt in Bengaluru) ((Neil.JKanatt@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}